Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5

Inclusion Criteria: * patients that have confirmed through genetic testing their status as carriers of 2 mutations in the CYP7B1 gene * age ≥ 18 years * patients that have signed the informed consent form * presence of health care coverage Exclusion Criteria: * known hypersensitvity to chenodeoxycholic acid, atorvastatin, resveratrol or to any of their byproducts * cholesterol lowering medications other than the study treatment * hepatic failure with transaminases \>3 times the normal level * progressive biliary pathology * chronic diarrhea * serious mental illness * significant comorbid neurological disorder * incapacity to understand information about the protocol * unwilling or unable to participate in any part of the study * participation in another clinical trial during the study period * person deprived of liberty by judicial or administrative decision * adult subject under legal protection or unable to consent * pregnant or breastfeeding women * lack of health care coverage * absence of a signed informed consent form